Cornelius Engelmann, Martina Sterneck, Karl Heinz Weiss, Silke Templin, Steffen Zopf, Gerald Denk, Dennis Eurich, Johann Pratschke, Johannes Weiss, Felix Braun, Martin-Walter Welker, Tim Zimmermann, Petra Knipper, Dirk Nierhoff, Thomas Lorf, Elmar Jäckel, Hans-Michael Hau, Tung Yu Tsui, Aristoteles Perrakis, Hans-Jürgen Schlitt, Kerstin Herzer, Frank Tacke
Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in liver transplant recipients, but their toxicity needs to be balanced against the benefits. The choice of prevention strategy (prophylaxis or preemptive treatment) depends on the donor/recipient sero-status but may vary between institutions. We conducted a series of consultations and roundtable discussions with German liver transplant center representatives...
July 23, 2020: Journal of Clinical Medicine